Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden-Reference-Cited by-同舟云学术

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

Published:2017-01-06 Issue:2 Volume:15 Page:237-248
ISSN:1175-5652
Container-title:Applied Health Economics and Health Policy
language:en
Short-container-title:Appl Health Econ Health Policy

Author:

Ericsson Åsa,Lundqvist Adam

Funder

Novo Nordisk

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics and Econometrics,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40258-016-0301-y.pdf

Reference60 articles.

1. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.

2. American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care. 2008;31(Suppl 1):S12–54.

3. Socialstyrelsen. Nationella riktlinjer för diabetesvården 2010 – Stöd för styrning och ledning 2010. http://www.socialstyrelsen.se/ . Accessed 22 Dec 2016.

4. International Diabetes Federation. Global guideline for type 2 diabetes 2012. https://www.idf.org/global-guideline-type-2-diabetes-2012 . Accessed 22 Dec 2016.

5. National Diabetes Register. NDR Statistik. https://ndrstatistik.registercentrum.se/ . Accessed 22 Dec 2016.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients;Diabetology & Metabolic Syndrome;2023-08-19

3. A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico;PharmacoEconomics - Open;2023-07-15

4. Editorial: Emerging talents in pharmacology: Drugs outcomes research and policies 2022;Frontiers in Pharmacology;2023-03-02

5. Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China;Frontiers in Pharmacology;2022-11-18